Nitromed to present new data on BiDil to treat heart failure

By Elaine Rigoli

Tampa, Fla., Sept. 11 - NitroMed, Inc. said that five poster presentations highlighting new findings related to BiDil (isosorbide dinitrate/hydralazine hydrochloride) will be presented at the annual meeting of the Heart Failure Society of America being held this week in Seattle.

The drug was approved in June 2005 on the basis of clinical results from the company's African American Heart Failure Trial (A-HeFT).

The first BiDil presentation demonstrates longer-term compliance with the fixed-dose combination drug, as well as continued efficacy, safety and tolerability. A second presentation highlights a particular genotype of the G protein beta 3-subunit that is closely associated with positive results in A-HeFT, providing a basis for further study for the role of the genotype in targeting therapy.

A third presentation demonstrates a survival benefit among post-menopausal women who received BiDil in A-HeFT, while the fourth presentation shows cardiac mortality as the most common cause of death in African American heart failure patients. The fifth presentation suggests that while BiDil was superior to a placebo with or without use of beta blockers or angiotensin converting enzyme inhibitors; there appears to be further benefit in the group treated with BiDil and beta blockers than without beta blockers.

NitroMed of Lexington, Mass., is an emerging pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.